CYCLERION THERAPEUTICS, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.1M | $2.0M | $0 | $297.0K | $3.9M | $2.3M | $4.5M |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $959.0K | $286.0K | $1.5M | $6.0M | $37.6M | $56.4M | $95.1M |
| SG&A Expense | $6.1M | $5.3M | $8.1M | $12.9M | $20.6M | $28.8M | $34.4M |
| Operating Income | $-5.0M | $-3.6M | $-13.0M | $-18.5M | $-55.2M | $-81.3M | $-125.0M |
| Operating Margin | -239.8% | -181.4% | — | -6,242.4% | -1,400.2% | -3,539.4% | -2,774.3% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-3.5M | $-3.1M | $-5.3M | $-44.1M | $-51.6M | $-122.4M | $-122.4M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-3.5M | $-3.1M | $-5.3M | $-44.1M | $-51.6M | $-77.8M | $-123.0M |
| Net Margin | -170.1% | -152.9% | — | -14,841.1% | -1,310.2% | -3,388.6% | -2,729.3% |
| EPS (Basic) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 | $-2.56 | $-4.49 |
| EPS (Diluted) | $-1.11 | $-1.21 | $-2.25 | $-20.28 | $-1.32 | $-2.56 | $-4.49 |
| Shares Outstanding (Basic) | 3.2M | 2.5M | 2.3M | 2.2M | 39.1M | 34.0M | 27.6M |
| Shares Outstanding (Diluted) | 3.2M | 2.5M | 2.3M | 2.2M | 39.1M | 34.0M | 27.6M |
| Dividends Per Share | — | — | — | — | — | — | — |